ACC.21 late-breaking clinical trial programme announced

2173

The American College of Cardiology (ACC) has announced a number of the late-breaking clinical trials to be presented at its 70th annual scientific session (ACC.21, 15–17 May, virtual).

The event has recently been switched to an all-virtual format having originally slated to be a hybrid event, with in-person sessions taking place in Atlanta, USA.

ACC said that the late-breaking clinical trial sessions will explore the latest research in the areas of ischemic heart disease, prevention and health promotion, electrophysiology, heart failure and cardiomyopathies, and more.

Some of the expected highlights include:

  • LAAOS III: The Left Atrial Appendage Occlusion Study III
  • Randomized Atlantis Trial: Oral Anti-xa Anticoagulation After Trans-aortic Valve Implantation For Aortic Stenosis
  • Results from the EXPLORER-HCM Randomized Clinical Trial: Health Status Benefits of Mavacamten In Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy
  • A Report From the NCDR LAAO Registry: One-year Clinical Outcomes Following Watchman Transcatheter Left Atrial Appendage Occlusion For Stroke Prevention In Patients With Atrial Fibrillation
  • 30-day Results of the Triscend Study: Transfemoral Tricuspid Valve Replacement In Patients With Tricuspid Regurgitation
  • Results From the Twilight Study: Sex-Specific Outcomes In High-Risk Patients Receiving Ticagrelor With Or Without Aspirin After Percutaneous Coronary Intervention
  • World Alliance Societies Of Echocardiography COVID Study: Human Vs Machine Learning-based Echocardiography Analysis As Predictor Of Outcomes In Acute Covid-19 Patients
  • ACC 2020 Well Being Study: Impact of COVID-19 on the Global Cardiovascular Workforce

LEAVE A REPLY

Please enter your comment!
Please enter your name here